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and Gary Kenneth Hulse1,2

Abstract: Background: Whilst many studies have linked increased drug and cannabis exposure to adverse mental
health (MH) outcomes their effects on whole populations and geotemporospatial relationships are not well
understood.
Methods: Ecological cohort study of National Survey of Drug Use and Health (NSDUH) geographically-linked
substate-shapefiles 2010–2012 and 2014–2016 supplemented by five-year US American Community Survey. Drugs:
cigarettes, alcohol abuse, last-month cannabis use and last-year cocaine use. MH: any mental illness, major
depressive illness, serious mental illness and suicidal thinking. Data analysis: two-stage, geotemporospatial, robust
generalized linear regression and causal inference methods in R.
Results: 410,138 NSDUH respondents. Average response rate 76.7%. When drug and sociodemographic variables were
combined in geospatial models significant terms including tobacco, alcohol, cannabis exposure and various ethnicities
remained in final models for all four major mental health outcomes. Interactive terms including cannabis were related to any
mental illness (β-estimate = 1.97 (95%C.I. 1.56–2.37), P < 2.2 × 10− 16), major depressive episode (β-estimate = 2.03 (1.54–2.52),
P = 3.6 × 10− 16), serious mental illness (SMI, β-estimate = 2.04 (1.48–2.60), P = 1.0 × 10− 12), suicidal ideation (β-estimate = 1.99
(1.52–2.47), P < 2.2 × 10− 16) and in each case cannabis alone was significantly associated (from β-estimate = − 3.43 (− 4.46 −
−2.42), P = 3.4 × 10− 11) with adverse MH outcomes on complex interactive regression surfaces. Geospatial modelling
showed a monotonic upward trajectory of SMI which doubled (3.62 to 7.06%) as cannabis use increased. Extrapolated to
whole populations cannabis decriminalization (4.26%, (4.18, 4.34%)), Prevalence Ratio (PR) = 1.035(1.034–1.036), attributable
fraction in the exposed (AFE) = 3.28%(3.18–3.37%), P < 10− 300) and legalization (4.75% (4.65, 4.84%), PR = 1.155 (1.153–1.158),
AFE = 12.91% (12.72–13.10%), P < 10− 300) were associated with increased SMI vs. illegal status (4.26, (4.18–4.33%)).
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Conclusions: Data show all four indices of mental ill-health track cannabis exposure across space and time and are robust
to multivariable adjustment for ethnicity, socioeconomics and other drug use. MH deteriorated with cannabis legalization.
Cannabis use-MH data are consistent with causal relationships in the forward direction and include dose-response and
temporal-sequential relationships. Together with similar international reports and numerous mechanistic studies preventative
action to reduce cannabis use is indicated.
Keywords: Cannabis, Cannabinoid, Δ9-tetrahydrocannabinol, Cannabigerol, Mental illness, Major depressive illness, Suicidal
ideation, Pathways and mechanisms

Background
It is widely understood that the use of addictive substances impacts mental health adversely. Cannabis use
has been linked with numerous adverse mental health
outcomes including reduced educational achievement
[1, 2], increased criminal involvement [3], reduced accomplishment of adult goals (education, employment,
stable long term relationships) [4], depression [5–7]
bipolar disorder [8–10], anxiety [7, 11–13], suicidality
[7, 10, 14, 15], schizophrenia, psychosis [16–23] and
other drug use [24].
Indeed one notes that the existence and mission of the
US Substance Abuse and Mental Health Services Administration (SAMHSA) aims to minimize the incidence
of both substance abuse and mental ill-health in order to
advance the behavioural health of the nation [25] and
that of the National Institute of Drug Abuse is not dissimilar [26]. As such it is widely perceived that substance
use may negatively impact major mental health outcomes. This issue was clearly crystallized by the Director
of the SAMHSA, Dr. Elinore McCantz-Katz in her presentation of the 2017 National Survey of Drug Use and
Health (NSDUH) results which showed in a nationally
representative sample of 18–25 year old young adults
from 2008 to 2017, a doubling of serious mental health
issues from 3.8 to 7.5% and of suicidal plans from 2.0 to
3.7% in the context of past month cannabis use rates rising from 17.3 to 22.1% but falling use of tobacco and alcohol products and low use rates of opioids and cocaine
use [27].
This implies that the unbridled adoption of the widespread use of new addictive psychoactive substances
may potentially have far-reaching psychological implications with possible impacts at the public health level. It
would appear inevitable that in view of the known adverse effects of cannabis on mental health at the molecular, cellular and epidemiological levels [28–33] its
widespread deployment in the community would necessarily be causally linked with numerous indices of deteriorating mental health. This was of particular concern in
USA in view of the appalling deterioration in the mental
health of young adults described in detail by SAMHSA
(above paragraph).

In the present context this applies particularly to cannabis use which, since the takeover of various cannabis
operations by major tobacco corporations, seems poised
at the threshold of major commercialization and global
launch by utilizing the global reach and marketing platform of what is popularly known as the “Big Tobacco”
industry. Notwithstanding its representation in popular
culture as a relatively harmless “soft” drug, cannabis use
has been shown to be linked with a variety of negative
mental health outcomes including cannabis dependency
and use disorder, an impaired lifetime trajectory and fulfilment of adult goals, an amotivational state, an increased incidence of graduation to use of other addictive
agents, depression, anxiety, bipolar disorder, schizophrenia and suicide [2, 4, 17, 24, 28, 34–40].
Such being the case one would expect patterns of
mental health to follow cannabis use across both time
and space. The NSDUH conducted annually by SAMH
SA is a globally unique drug dependency and mental
health research resource which allows investigation of
both substance use and mental health at relatively high
spatial and temporal resolution. Its availability publicly
together with the presence of high definition substate
shapefiles which link these parameters geospatially at defined time points, and which can be matched with other
datasets such as those available through the US census,
presents a globally unique opportunity to conduct an
important public health investigation of these potentially
related trends.
The hypothesis driving the present ecological epidemiological investigation was firstly, that substance use
and mental health are linked in a formally demonstrable
manner, and secondly, that increasing rates of cannabis
use would be reflected at the level of population health
trends in a robust manner which persisted after adjustment for other common sociodemographic variables.
These hypotheses was formulated prior to study commencement. We considered that it was important to use
modern geospatiotemporal regression and the tools of
formal causal inference in investigating these questions
and associations, and in particular in assessing the potentially causal nature of the relationship. A corollary of
this is that one might expect metrics of mental health to

Reece and Hulse BMC Public Health

(2020) 20:1655

be worse in states where cannabis is legal. This hypothesis was also tested.
Whilst a link between substance use and adverse mental health is well described in various clinical contexts
what is not clear is the extent to which the mental
health of whole populations is impacted with particular
reference to trends across both space and time and considerations of a putatively causal relationship. It was
these gaps that the present research aimed to fill.
It follows that such an enquiry is particularly timely at
the present juncture given what appears to be a clear
and present international threat to global mental health.
On the international scene cannabis is clearly enjoying a
modern renaissance under its falsely reassuring image as
a low toxicity compound. If concerning trends can be
identified and described in USA then it follows that such
concerns are likely to apply elsewhere, most particularly
if the causal nature of the relationship could be demonstrated at the population health level. For these reasons
the present study was timely and important not only for
the health of Americans, but indeed to protect the global
community of nations.
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and schizophrenia [43].US Census Bureau County data
on ethnicity and median household income (MHY) was
downloaded from the via the tidycensus package in R
using shapefiles from the R package tigris. Sociodemographic data was derived from the 5 year American
Community Survey (ACS, “acs5”) conducted by US Census. The two NSDUH shapefiles were centred on 2011
and 2015 so they were matched to the ACS 2009–2013
and ACS 2013–2017 respectively. Each respective ACS
shapefile was then interpolated into the substate area
definitions provided by SAMHSA. The two combined
NSDUH shapefiles were then combined together with
the 2014–2016 NSDUH shapefile as the standard (or
“target”) file. Data for Alaska and Hawaii was treated
separately and then added in to the final shapefile and
elided (moved) into their appropriate positions for illustration purposes.
Data on the concentration of cannabinoids in federal
seizures of cannabis to 2011 has been published [44, 45].
In 2011 the concentration of tetrahydrocannabinol
(THC) was 11% and it has been increasing by about 1%
annually. Projected forwards this provides an estimate of
15% in 2015.

Methods
Data

Statistics

NSDUH Data on drug use by area was downloaded from
the publicly available NSDUH SAMHSA substate shapefiles for 2010–2012 and 2014–2016 [41, 42]. A NSDUH
shapefile for 2012–2014 exists but as it substantially
overlaps the other two its inclusion would significantly
complicate the analysis so this has not been used. This
implies that data for 2015 was not used in the present
analysis. On occasion the triennia were referred to by
their middle year, hence 2011 and 2015. Over 405,000
participants were surveyed across the 6 years. The
2014–2016 shapefile divides the USA into 395 substate
areas based either on county or congressional district
boundaries. The four drugs of interest were last month
cigarette use, past year alcohol abuse or dependence, last
month cannabis use, and last year cocaine use which are
abbreviated to cigmon, abodalc, mrjmon and cocyr in
the NSDUH documentation. These drugs were treated
as covariates for cannabis use. Unfortunately no consistent nomenclature for opioid exposure could be identified across both shapefiles. The four mental illnesses
mentioned in the NSDUH shapefiles are any mental illness in the past year, major depressive episode, serious
mental illness in the past year and suicidal thinking
whose NSDUH abbreviations are amiyr, mde, smiyr and
suithyr. Serious mental illness is defined as a “mental,
behavioural or emotional disorder resulting in severe
functional impairment which substantially interferes
with one or more major life activities” and includes the
diagnoses of major depression, bipolar affective disorder

The analysis was conducted in January 2020. Data was
processed in “R” from CRAN using several packages including tidyverse, tidycensus, tigris, sp., sf, spdep and
splm. Graphs and maps were drawn in ggplot2. Hawaii
and Alaska were elided for illustration in sp. (spatial
modelling), converted back to sf (simple features) and
rendered in the USA contiguous Albers Equal Area Conical projection EPSG:102003 as in the R package albersusa. Disparate geographical boundaries were conformed
using R::areal. Statistical model reduction from first to
final models was by the classical technique of sequential
elimination of the least significant term until only significant terms remain.
The formal analysis of spatially distributed data is not
methodologically trivial but requires dedicated methods
in order to account for the spatial relationships by which
many variables interact and are dependent on each
other. In 1970 Waldo Tobler described the first law of
geography when he noted that things nearby interact
more than things far away [46]. It is important to take
this spatial autocorrelation into account when analyzing
spatially distributed variables. The package splm in the
“R” computing environment is purpose built for such applications. In particular it includes the spatial panel generalized method of moments (spgm) function which is
ideally suited to short panel datasets such as this one
and the spatial panel random error maximum likelihood
(spreml) function which includes sophisticated methods
to account for various spatial lag and error structures.
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Both techniques allow the use of instrumental variables.
Thus both techniques have been applied to this dataset.
Geospatiotemporal data processing was done using the
“R” package splm (spatial panel linear modelling) with
the spatial panel generalized method of moments (spgm)
function as it is ideally suited to short panel data such as
this and also with the recent spml refinement spreml
(spatial panel random error maximum likelihood) function which incorporates sophisticated modelling of error
and autocorrelation structures. The standard spgm
model was spatially lagged, used the full weights method,
a generalized two-step least squared estimation method,
spatial error and lagged the instrumental variables. Instrumental variables were the local cannabis ethnic potency index (LCEPI) defined below. For spreml models
the full model was used including spatial lagging, spatial
errors of Kapoor, Kelejian and Prucha [47], autocorrelation order 1 errors and the same ethnic instrumental
variables as above. Spatial errors and spatial weights
were calculated using the spdep::poly2nb function and
these data were updated to include conceptual links
from the Hawaiian islands to south-eastern California
and from Alaska to Washington state and Oregon.
Modelling of fitted values was done by matrix multiplication of mean, minimum and maximum values into
model coefficients as indicated. Analysis of the impact of
cannabis legal status at state level was undertaken from
the state-based NSDUH data table (“state_saes_final.sas7bdat”) supplemented by cannabis legal status defined
from an internet search. Data was manipulated with
dplyr and the resulting two-by-two tables were analyzed
in epiR.

Causal inference analysis

Inverse probability weighting was conducted for the
whole sample using the R package ipw. This transforms
our study from merely ecological and observational to a
pseudo-randomized design where causal inferential relationships can properly be assigned. These weights were
then entered into robust generalized linear regression
using the R package survey with substate region as the
identifying variable. In order to calculate a model standard deviation the weights were also utilized in mixed effects regression using the R package nlme again with
substate region as the grouping variable.
The e-Value is a new index which was recently defined
[48] which quantitates the degree of association with
both the exposure and the outcome which would be required of an unmeasured confounding variable to explain away the observed significant finding [48–53]. It is
presented on the risk ratio scale. Research literature
commonly contains e-Values of 1.25 and above [52]. eValues were computed from relative risks and regression
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coefficients using the R package EValue. P < 0.05 was
considered significant throughout.
Data availability statement

Data including shapefiles and R programming script is
made publicly available on the Mendeley Data Archive
at this URL:
https://doi.org/10.17632/gyckst6rx8.1. The original
SAMHSA shapefiles may be found at https://www.
samhsa.gov/data/report/2014-2016-nsduh-substate-region-shapefile and https://www.samhsa.gov/data/report/2012-2014-nsduh-substate-region-shapefile.
Ethics

Ethical approval for this study was provided by the University of Western Australia Human Research Ethics
Committee 08/01/2020 (No. RA/4/20/4724).

Results
Of 534,000 individuals approached 410,138 responded to
the six NSDUH surveys, a completion rate of 76.7%.
Data for the 2 years 2011 and 2015 are listed as median
and interquartile ranges and compared nonparametrically in Supplementary Table 1.
Figure 1 shows the rates of mental illness for the four
NSDUH-defined mental health disorders included in the
SAMHSA substate shapefiles of any mental illness,
major depressive episode, serious mental illness and suicidal thinking.
Figure 2 shows map-graphically the distribution of the
use of various drugs across USA in the two NSDUH
triennia.
Figure 3 shows the rates of the four mental illness syndromes by drug use at state level. The slope (as βestimates) and significance of these regression lines is
shown in Supplementary Table 2. The slopes for three
of the lines is significant.
Supplementary Fig. 1 shows the ethnic composition of
USA for the two periods.
Supplementary Fig. 2 shows the rate of median household income in the USA in the two periods 2010–2012
and 2014–2016.
National level NSDUH data make it clear that there
are considerable differences between various ethnicities
in drug use and especially daily / near daily cannabis
use. These can be averaged out by ethnicity to derive a
cannabis use frequency index at the national level. It is
likely that regional data also impacts cannabis use by
ethnic populations so an index of this was derived by
multiplying the local monthly cannabis use by the national ethnic near daily cannabis use to derive a local
cannabis ethnic daily index (LCEDI) at state level. Since
the THC concentration of cannabis has also been increasing the LCEDI can in turn be multiplied by the
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Fig. 1 Mental Illness across USA by substate area. Data from NSDUH Shapefiles

THC content to produce a local cannabis ethnic daily
potency index (LCEDPI) of local ethnic exposure to cannabinoids. This LCEDPI index may also be referred to as
an “Ethnic score” and it has been used as an important
instrumental variable controlling for environmental cannabinoid exposure arising from the sociocultural environment rather than any intrinsic ethnic risk propensity
(such as pharmacogenomic susceptibilities). The various
LCEDI and LCEDPI are listed in Supplementary Table 3
and illustrated in Supplementary Figs. 3 and 4.
Supplementary Fig. 5 shows the relative rise in these indices from the 2010–2012 baseline and the relative rise
comparable to the mean rise by ethnicities.
First degree edge and corner (“queen”) spatial weights
were calculated between substate areas by R::spdsep::
poly2nb and updated for Alaska, Hawaii and Richmond
Island (in New York) as shown in Supplementary Fig. 6A,
with final results as shown in Supplementary Fig. 6B.
Supplementary Table 4 presents the spgm results
when serious mental illness is regressed against each of
drugs, median household income, and ethnicity variables
separately with the ethnic LCEPI included as instrumental variables. As noted, only the drug related variables
are significant. Terms including cannabis are significant

Fig. 2 Drug Use across USA by substate area. Data from NSDUH Shapefiles

(from β-estimate = 0.08 (95%C.I. 0.02–0.13), P = 0.009).
Supplementary Table 5 performs the same task for serious mental illness using spreml regression. The significance level of all terms is increased. Both income and
racial composition now become significant. Terms including cannabis are significant (from β-estimate = 2.34
(1.71–2.97), P = 1.4 × 10− 13).
All the independent variables were then included in a
final spgm model shown in Table 1 for all four mental
illnesses listed by SAMHSA. All four described drugs
survive model reduction and appear in final models. The
table is notable for the high level of significance of many
drugs including terms involving cannabis (from βestimate = 1.74, (0.97, 2.51), P = 9.9 × 10− 6). Income and
ethnic factors do not survive model reduction. Hence
final models include drug related factors only.
Table 2 presents results from a similar exercise applying the advanced techniques of spreml spatial regression.
Again all four drugs are included at high level of significance. Terms including cannabis appear (from βestimate = 1.84 (0.30, 2.39), P ≤ 3.0 × 10− 11) for all four
illness syndromes. Terms including cannabis appear
(from β-estimate = − 3.31 (2.58, 4.04), P ≤ 2.2 × 10− 16 for
any mental illness and (from β-estimate = 2.13 (1.63,
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Fig. 3 Mental Illness by Substance Exposure. Data from NSDUH Shapefiles

2.62), P ≤ 2.2 × 10− 16) for major depressive episode. Ethnic factors appear in all models. Median household income only appears in the model for serious mental
illness.
As mentioned spreml models give advanced access to
the error structure of spatial models. It is therefore
mandatory to give careful attention to correct model
specification. Supplementary Table 6 shows a selection
of the principal error structures and their various specifications. The log maximal likelihood of the models is
listed at model optimization, together with the value of
the spatial Hausman test comparing each model to the
full model. In each case high levels of statistical significance are demonstrated with all P < 2.2 × 10− 16. These
results confirm that the model specification which was
presented above, namely the full sem2srre + lag model, is
technically correct.
The rates of mental illness can be aggregated into state
areas to compare mental illness rates by the legal status
of cannabis.
The final spreml model for serious mental illness may
be used to compute fitted values. When mean values for

tobacco and alcohol abuse together with minimum or
maximum values for monthly cannabis use are entered
into this model minimum and maximum values for serious mental illness of 3.62 and 7.06% result (maximum =
1.95-fold minimum value). Figure 4a shows the modelled
rate of serious mental illness as a function of cannabis
use decile (Supplementary Table 7).
Data also lend themselves to analysis by the formal techniques of causal inference. Inverse probability weights
were calculated as described and entered into robust generalized linear regression equations. The effect of conducting regression procedures with inverse probability weights
is to make the sample pseudo-randomly conducted with
regard to the exposure of interest, in this case cannabis
use, so that the outcome can be properly assessed without
the confounding arising from the exposure being nonrandomly distributed across the other covariate exposure
groups. The results of final models from additive and
interactive models as shown in Table 3. In this Table the
dependent variable is serious mental illness rates and the
list of covariates includes five racial groups, median household income, ethnic cannabis use scores (LCEDI) and
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Table 1 Spatial panel general method of moments regression – final models
General
Instrumental Variables

Parameters
Parameter

Model
Estimate (95%C.I.)

P-Value

Para-meters

Value

P-Value

Any Mental Illness
NHWhite_Score

spgm (amiyr ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine + Med_HH_Income + 5_Races)

NHBlack_Score

Cigarettes: Cannabis: Alcohol_Abuse

−0.05 (− 0.07--0.03)

2.5E-05

rho

− 0.5152

N/A

Hispanic_Score

Cigarettes: Alcohol_Abuse

0.11 (0.06–0.16)

4.6E-05

sigma^2_

0.003

N/A

NHAsian_Score

Cannabis: Alcohol_Abuse

1.21 (0.61–1.81)

7.9E-05

lambda

0.6753

1.30E-05

NHAIAN_Score

Cigarettes: Cannabis

0.09 (0.05–0.13)

0.0001

Alcohol_Abuse

−2.43 (−3.72--1.14)

0.0002

Cigarettes

−0.17 (− 0.26--0.08)

0.0003

Cannabis

−1.99 (−3.08--0.9)

0.0004

Cocaine

0.05 (0.01–0.09)

0.0128

Median_Household_Income

−0.03 (− 0.06–0)

0.0339

Afr.Am_Pop_Fraction

0.03 (0–0.06)

0.0485

Major Depressive Episode
NHWhite_Score

spgm (mde ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine + Med_HH_Income + 5_Races)

NHBlack_Score

Cannabis: Alcohol_Abuse

1.74 (0.97–2.51)

9.9E-06

rho

−0.6813

N/A

Hispanic_Score

Cigarettes: Cannabis: Alcohol_Abuse

−0.07 (− 0.1--0.04)

2.6E-05

sigma^2

0.005

N/A

NHAsian_Score

Cannabis

−2.98 (− 4.38--1.58)

2.9E-05

lambda

0.8945

1.20E-04

NHAIAN_Score

Alcohol_Abuse

−3.46 (−5.1--1.82)

3.8E-05

Cigarettes: Cannabis

0.12 (0.06–0.18)

6.3E-05

Cigarettes: Alcohol_Abuse

0.13 (0.06–0.2)

8.1E-05

Cigarettes

−0.23 (− 0.35--0.11)

2.4E-04

Serious Mental Illness
NHWhite_Score

spgm (smiyr ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine + Med_HH_Income + 5_Races)

NHBlack_Score

Cigarettes: Alcohol_Abuse

0.1 (0.03–0.17)

0.0048

rho

− 0.7386

N/A

Hispanic_Score

Cigarettes

−0.17 (− 0.29--0.05)

0.0058

sigma^2

0.0055

N/A

NHAsian_Score

Cigarettes: Cannabis: Alcohol_Abuse

−0.04 (− 0.07--0.01)

0.0082

lambda

0.7722

3.37E-07

NHAIAN_Score

Cocaine

0.07 (0.02–0.12)

0.0087

Cigarettes: Cannabis

0.08 (0.02–0.14)

0.0092

Alcohol_Abuse

−2.14 (−3.82--0.46)

0.0126

Cannabis: Alcohol_Abuse

0.96 (0.17–1.75)

0.0169

Cannabis

−1.66 (−3.09--0.23)

0.0231

−0.6752

N/A

NHWhite_Score

Suicidal Thoughts Past Year

NHBlack_Score

spgm (suithyr ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine + Med_HH_Income + 5_Races)

Hispanic_Score

Alcohol_Abuse

−3.05 (− 4.67--1.43)

0.0002

rho

NHAsian_Score

Cannabis: Alcohol_Abuse

1.37 (0.61–2.13)

0.0004

sigma^2_

0.0051

N/A

NHAIAN_Score

Cigarettes: Alcohol_Abuse

0.12 (0.06–0.18)

0.0004

lambda

0.7757

7.96E-12

Cigarettes: Cannabis: Alcohol_Abuse

−0.05 (− 0.08--0.02)

0.0012

Cigarettes

−0.19 (− 0.31--0.07)

0.0016

Cannabis

−2.18 (−3.55--0.81)

0.0019

Cigarettes: Cannabis

0.08 (0.02–0.14)

0.0037

Abbreviations
5_Races: Caucasian-American, African-American, Hispanic-American, Asian-American, NHAIAN
Technical Notes:
phi:- Idiosyncratic component of the spatial error term
psi:- Individual time-invariant component of the spatial error term
rho:- Spatial autoregressive parameter
lambda:- Spatial autocorrelation coefficient
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drug use variables for cigarettes, binge alcohol, monthly
cannabis and annual cocaine. In additive models both cannabis use (β-estimate = − 0.43 (− 0.65 - -0.21), P = 0.0002),
and Caucasian American cannabis use (β-estimate = 0.95
(0.05–1.85), P = 0.0396) survived model reduction and
were significant. In models including a four-way cigarette:
alcohol:cannabis:cocaine interaction, terms including cannabis were significant from (β-estimate = 0.12 (0.10, 0.14),
P < 10− 16).
In inverse probability weighted mixed effects additive
and interactive models with the same list of dependent
variables and predictive covariates, terms including cannabis were again significant (from β-estimate = 0.11
(0.07, 1.15), 1.5 × 10− 5; Supplementary Table 8).
Sensitivity analyses may be conducted on these odds
ratio, mixed effects and geospatial data with many highly
significant e-Value results as shown in Supplementary
Table 9. The minimal e-values in the geotemporospatial
analyses ranged from 3.13 to 2,660,000 (Supplementary
Table 9). This compares positively to comments in the
literature that e-Values above 1.25 are often quoted in
scientific reports [52]. Such elevated values make uncontrolled confounding extremely unlikely and point to a
relationship which is truly causal in nature.
When one considers state-based data for the 6 years
of the NSUDH shapefiles states with legal cannabis
status had an increased rate of serious mental illness
(Prevalence ratio (PR) = 1.09 (95%C.I. 1.04, 1.13), attributable fraction in the exposed (AFE) = 7.93% (4.17,
11.55%), attributable fraction in the population
(AFP) = 0.70% (0.035, 1.06%), Chi.Squ. = 16.25, df = 1,
P = 5.55 × 10− 5).
Figure 4b and Table 4 show the mean rate of serious
mental illness as a function of cannabis legal status when
NSDUH results are extrapolated onto whole state populations. The values for the Illegal, Medical, Decriminalized and Legal Status are 4.26 (4.18, 4.34%), 4.11 (4.01,
4.21%), 4.01 (3.83, 4.19%) and 4.75 (4.65, 4.85%) respectively. The notches for the Decriminalized and Legal statuses are noted to not overlap those of the illegal status.
Cannabis decriminalization was associated with an increased incidence of serious mental illness (PR = 1.035
(1.034, 1.036), AFP = 3.28% (3.18, 3.37%), AFE = 1.13%
(1.09, 1.16%), ChiSq. = 4635.1, df = 1, P < < 10− 300), as
was cannabis legalization (PR = 1.155 (1.153, 1.158),
AFE = 12.91% (12.72, 13.10%), AFP = 0.83% (0.82, 0.85%),
ChiSq. = 15,015.1, df = 1, P < < 10− 300).
Supplementary Fig. 7 shows the rate of all mental illness syndromes against cannabis legalization status from
state based data. The Chi-squared comparisons are
shown in Supplementary Table 10. Results for any mental illness and suicidal ideation are both significant (P =
0.0395 and P = 0.0395) are that for serious mental illness
approaches significance (P = 0.0654).
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Discussion
Main findings

This study applies current geospatial techniques to the
analysis of the four metrics of mental illness spatially described by SAMHSA in recent iterations of NSDUH.
Using spatial panel generalized method of moments
(spgm) techniques drug-related variables pertaining to
tobacco, alcohol, abuse cannabis and cocaine were found
to be more significant than socioeconomic and ethnographic factors after correction using estimates for increased local exposure to cannabis in some ethnic
groups. For cannabis this included terms significant
from P < 10− 5. When more advanced spatial techniques
such as the full spatial panel random error maximum
likelihood (spreml) models were used these results were
confirmed overall and included an increased level of
statistical significance for terms including cannabis for
all four mental illness metrics from P < 4.0 × 10− 11.
Therefore geospatial techniques increased the precision
of the parameter estimates by several orders of
magnitude.
It is of interest to consider these findings in the light
of the remarks mentioned in the Introductory section relating to the poor and declining mental health of US
young adults. First, there is a very obvious association
nationally with the dramatic decline in the mental health
of young adults in the USA and rising levels of cannabis
use in that age demographic [27, 54]. Our results confirm this trend at the higher geospatial resolution of the
substate level.
Secondly both study hypotheses are confirmed by
study results. All indices of mental health (any mental
illness, major depressive illness, serious mental illness
and suicidal ideation) are robustly associated with the
use of all addictive substances investigated. It is equally
clear that the hypothesized relationships between cannabis and all four indices of mental ill-health are not only
established, but robust to multivariable adjustment.
Moreover analysis of the data with inverse probability
weights in both mixed effects models and robust generalized linear models together with sensitivity analyses indicated that the relationship fulfilled the criteria of
causality in each case.
Any mental health issues and suicidal ideation were
also shown to be worse in parallel with liberalized cannabis policies. The result for serious mental illness
approached significance (P = 0.06).
Pathways and mechanisms

Since the existence of plausible biological pathways
explaining a potential causal pathway from cannabis exposure to mental illness is a foundational pillar of causal
algorithms such as that of Hill [55] it becomes very important to consider briefly some of the neurotoxic
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Table 2 Spatial panel random error maximum likelihood regression – final models
General

Parameters

Model

Instrumental Variables

Parameter

Estimate (95%C.I.)

P-Value

Para-meters

Value

P-Value

Any Mental Illness
spreml (amiyr ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine + Med_HH_Income + 5_Races)
−4.19 (− 5.02--3.36)

NHWhite_Score

Alcohol_Abuse

< 2.2e-16

NHBlack_Score

Cannabis: Alcohol_Abuse

1.96 (1.55–2.37)

< 2.2e-16

psi

0.4002

0.251

Hispanic_Score

Cannabis

−3.33 (−4.06--2.6)

< 2.2e-16

rho

−0.1507

0.3296

NHAsian_Score

Cigarettes: Alcohol_Abuse

0.15 (0.11–0.19)

< 2.2e-16

lambda

0.2336

0.0425

NHAIAN_Score

Cigarettes

−0.26 (−0.32--0.2)

4.00E-15

Cigarettes: Cannabis: Alcohol_Abuse

−0.07 (− 0.09--0.05)

2.70E-15

Cigarettes: Cannabis

0.12 (0.09–0.15)

1.20E-13

0.1573

0.9579

Caucasian-Amer.Pop_Fraction

0.09 (0.06–0.12)

1.00E-10

Median_Household_Income

−0.09 (− 0.12--0.06)

1.30E-06

Hispanic_Pop_Fraction

−0.01 (− 0.02–0)

0.0033

African-Amer._Pop_Fraction

−0.01 (− 0.02–0)

0.0062

Asian_Pop_Fraction

0.02 (0.01–0.03)

0.0131

phi

0.008

0.9908

Major Depressive Episode
spreml (mde ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine + Med_HH_Income + 5_Races)
NHWhite_Score

Cannabis: Alcohol_Abuse

2.03 (1.54–2.52)

3.60E-16

phi

NHBlack_Score

Alcohol_Abuse

−4.14 (−5.14--3.14)

4.90E-16

psi

0.3124

0.8569

Hispanic_Score

Cannabis

−3.53 (− 4.41--2.65)

3.80E-15

rho

−0.3358

0.0325

NHAsian_Score

Cigarettes: Alcohol_Abuse

0.16 (0.12–0.2)

1.60E-12

lambda

0.3809

0.0002

NHAIAN_Score

Cigarettes: Cannabis: Alcohol_Abuse

−0.08 (−0.1--0.06)

1.90E-12

Cigarettes

−0.27 (− 0.35--0.19)

4.50E-12

Cigarettes: Cannabis

0.14 (0.1–0.18)

5.70E-12

Caucasian-Amer._Pop_Fraction

0.08 (0.05–0.11)

2.20E-08

Hispanic_Pop_Fraction

−0.02 (−0.03−−0.01)

0.0003

African-Amer._Pop_Fraction

−0.01 (− 0.02–0)

0.0025

AIAN_Pop_Fraction

-0.01 (−0.02–0)

0.0085

Median Household Income

−0.04 (− 0.07--0.01)

0.0312

Serious Mental Illness
spreml (smiyr ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine + Med_HH_Income + 5_Races)
NHWhite_Score

Caucasian-Amer.

0.21 (0.17–0.25)

< 2.2e-16

phi

0.176

NA

NHBlack_Score

Median Household Income

−0.22 (−0.27--0.17)

< 2.2e-16

psi

0.153

NA

Hispanic_Score

Alcohol_Abuse

−4.55 (−5.69--3.41)

6.20E-15

rho

0.1311

0.2141

NHAsian_Score

Cannabis: Alcohol_Abuse

2.04 (1.48–2.6)

1.00E-12

lambda

0.0618

0.4449

NHAIAN_Score

Cannabis

−3.44 (−4.46--2.42)

3.40E-11

Cigarettes:Alcohol_Abuse

0.17 (0.12–0.22)

7.60E-11

Cigarettes

−0.27 (−0.36--0.18)

1.50E-09

Cigarettes: Cannabis: Alcohol_Abuse

−0.08 (− 0.11--0.05)

2.90E-09

Cigarettes: Cannabis

0.13 (0.08–0.18)

2.00E-08

African-Amer._Pop_Fraction

−0.02 (−0.03--0.01)

9.30E-06

Hispanic_Pop_Fraction

−0.02 (− 0.03--0.01)

0.005

Asian_Pop_Fraction

0.02 (0–0.04)

0.0089

Suicidal Thoughts Past Year
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Table 2 Spatial panel random error maximum likelihood regression – final models (Continued)
General

Parameters

Model

Instrumental Variables

Parameter

Estimate (95%C.I.)

P-Value

Para-meters

Value

P-Value

spreml (suithyr ~ Cigarettes * Cannabis * Alcohol_Abuse + Cocaine + Med_HH_Income + 5_Races)
NHWhite_Score

Alcohol_Abuse

−4.36 (−5.33--3.39)

< 2.2e-16

phi

0.0225

0.9737

NHBlack_Score

Cannabis: Alcohol_Abuse

1.99 (1.52–2.46)

< 2.2e-16

psi

0.1854

0.726

Hispanic_Score

Cannabis

−3.4 (−4.26--2.54)

1.05E-14

rho

−0.1314

0.2451

NHAsian_Score

Cigarettes: Alcohol_Abuse

0.16 (0.12–0.2)

6.72E-13

lambda

0.2824

0.0005

NHAIAN_Score

Cigarettes

−0.26 (− 0.34--0.18)

8.28E-12

Cigarettes: Cannabis: Alcohol_Abuse

−0.07 (− 0.09--0.05)

8.14E-11

Cigarettes: Cannabis

0.12 (0.08–0.16)

7.25E-10

Hispanic_Pop_Fraction

−0.02 (−0.03--0.01)

5.53E-08

African-Amer._Pop_Fraction

−0.02 (− 0.03--0.01)

2.89E-07

Caucasian-Amer._Pop_Fraction

0.07 (0.04–0.1)

1.12E-06

Asian_Pop_Fraction

0.03 (0.02–0.04)

1.03E-05

Median Household Income

−0.08 (−0.12--0.04)

5.70E-05

Abbreviations
5_Races: Caucasian-American, African-American, Hispanic-American, Asian-American, NHAIAN
Technical Notes:
phi:- Idiosyncratic component of the spatial error term
psi:- Individual time-invariant component of the spatial error term
rho:- Spatial autoregressive parameter
lambda:- Spatial autocorrelation coefficient

mechanisms which have been described in the published
literature. We note that numerous biological pathways
have been described linking cannabinoid exposure to
neurotoxicity and adverse neuropsychiatric outcomes.
Several genetic and epigenetic pathways have been

described linking altered dopamine receptor gene and
other gene expression with addictive, behavioural and
autistic outcomes [56–60]. Cannabinoids have been
shown to have adverse effects on neural stem cell activity [61] which negatively and importantly impacts brain

Fig. 4 Modelled Relationships and Legal Status. a Serious Mental illness by Rising Cannabis Concentration. b Serious Mental Illness by
Legal Status
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Table 3 Robust Generalized Linear Models Results

effect on cell growth, macromolecular synthesis and cell
division [72, 73] and adversely affects the slit:robo ratio
which controls the hypertrophic exuberant growth of
the massive human cerebral cortex [74–76].
It is also important to appreciate that such negative
cellular mechanisms have been ascribed to cannabinoids
other than simply Δ9-tetrahydrocannabinol as other
chemical moieties, including cannabidiol, cannabichromene and cannabinol have been similarly implicated
[77–80]. Indeed it is known that cannabis oil is toxic to
many plants including the leaves of Cannabis sativa itself [81].
It is also relevant in this regard that both the epigenetic actions and chromosomal mis-segregation actions of
cannabinoids imply not only genotoxicity and epigenotoxicity in the exposed individuals themselves, but also
heritable changes to several subsequent generations [82].
As the use of cannabis becomes both more widespread
and consumption increases in existing users, cannabinoid exposure will likely become multigenerational and
open new routes to cannabinoid-induced heritable neuropsychopathology. This was recently shown for autism
in USA [83, 84].
Whilst this study relates to the mental health of adults
it has been shown that cannabis use is linked with adverse mental health outcomes in offspring of exposed
populations including autism and ADHD-like changes
[83–94]. This important datum further amplifies the significance of the present investigation into the crossgenerational context.
Hence taken together these data overall clearly indicate not only that increased cannabis use is causally associated with adverse mental health outcomes at the
statistical and epidemiological level, but that multiple
biological pathways exist to explain the causal relationship mechanistically. Indeed data in this report indicates
that the cannabis-mental illness relationship fulfills all
ten of Hill’s criteria for causal relationships [55], in
addition to the unequivocal demonstration of very close
relationships across space and time and the results of
the causal inferential techniques employed.

Parameter

Estimate

C.I.

P-Value

Cocaine

0.27

(0.13–0.41)

7.6E-05

Alcohol

0.09

(0.05–0.13)

0.0001

Asian.Am

0.12

(0.06–0.18)

0.0005

Median Household Income

0.22

(0.06–0.38)

0.0041

Cauc.Am.Cannabis

0.95

(0.05–1.85)

0.0396

Cannabis

−0.43

(−0.65--0.21)

0.0002

Cigarettes

−0.02

(−0.04–0.00)

6.2E-05

Afric.Am

−0.09

(−0.13--0.05)

5.8E-06

Hispanic

−0.22

(−0.32--0.12)

2.4E-06

Cigarettes: Alcohol

0.06

(0.04–0.08)

3.2E-26

Cigarettes: Cannabis

0.12

(0.10–0.14)

1.5E-21

Asian.Am

0.07

(0.05–0.09)

4.0E-19

Alcohol: Cannabis

0.51

(0.39–0.63)

2.7E-17

Alcohol: Cannabis: Cocaine

0.04

(0.02–0.06)

2.2E-07

Afric.Am.Cannabis

−0.19

(−0.27--0.11)

3.8E-05

Alcohol: Cocaine

−0.07

(−0.11−− 0.03)

1.9E-05

AIAN.Am

-0.03

(−0.03--0.03)

3.7E-07

Cigarettes: Alcohol: Cannabis

−0.02

(−0.02--0.02)

2.0E-18

Afric.Am

−0.05

(−0.07--0.03)

4.0E-20

Alcohol

−1.41

(−1.65--1.17)

2.0E-26

Cigarettes

−0.30

(−0.36--0.24)

6.4E-28

Cannabis

−2.75

(−3.20--2.30)

3.4E-28

Additive Models

Interactive Models

plasticity and brain aging [62]. Cannabinoids can also induce microglial activation and priming [63] which was
recently shown to set the brain on a pathway which
phenocopies aging [64]. Cannabis exposure has also
been shown to age the human organism in a longitudinal study of cardiovascular ageing [64]. Cannabinoids
have been shown to decouple both synapses, by negatively impacting the neurexin-neuroligin machinery
which scaffolds them [65–68], and grey-white matter
coupling [69]. Similarly cannabinoids negatively impact
both actin and tubulin expression and dynamics [65]
impacting axonal guidance and growth cone mechanics
[70] and chromosomal mechanisms, chromosomal segregation and cell division [71]. Cannabis has a negative

Strengths and limitations

Our study has a number of strengths and limitations. Its
strengths include investigation of what we believe to be

Table 4 Serious mental illness prevalence ratios by legal status
Status

Serious Mental
Illness Cases

No. Using Cannabis
Last Month

Population

Proportion with Serious
Mental Illness

Proportion Using
Cannabis Last Month

Decriminalized

6,106,622

12,033,634

143,356,702

4.26% (4.18, 4.34%)

8.39%

Illegal

11,650,796

17,995,589

283,172,529

4.11% (4.01, 4.21%)

6.35%

Legal

805,083

2,337,511

16,936,978

4.75% (4.65, 4.85%)

13.80%

Medical

7,394,236

16,516,827

184,526,713

4.01% (3.83, 4.19%)

8.95%
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the best most carefully geospatially and temporally defined dataset in the world which measures both drug use
and mental health outcomes in a synchronized and coordinated manner. Also we believe that the application of
modern advanced geospatial analysis to these public
health problems is also new and novel and innovative.
The limitations of this study relate mainly to its ecological design. For example we had to estimate local use
of cannabis by ethnic origin as substate estimates were
not available. Similarly individual respondent data from
the survey is not available outside of dedicated US research centres and it is clear that access to such data
would increase the power of the present investigation.
We feel therefore that while the present analysis represents an important contribution to the literature in the
field it also provides a strong impetus for further
research.
Generalizability

Given that NSDUH is conducted carefully in a nationally
representative manner of the non-institutionalized adult
US population the present results are likely to be
generalizable to other developed nations. Moreover as it
appears that the geospatially observed trends are rooted
in the biological processes and mechanisms, what we are
seeing at the public health level reflects downstream
pharmacological effects from altered biological processes
occurring in human neurophysiology. We note that all
five of the major racial groups investigated herein
showed significant statistical relationships with mental
health metrics suggesting cross-racial effects.

Conclusions
Our interpretation of these results is that all four of the
adverse mental health outcomes mapped geotemporospatially by SAMHSA are linked upon formal geospatial
analysis with the use of all four of the addictive drugs
for which data was available. On testing of single domains of variables against serious mental illness only the
drug group was significant, whilst median household income and racial profiling were not. After adjustment for
the usual battery of ethnic, drug use and socioeconomic
covariates, terms including cannabis were significantly
linked with all four domains of mental ill-health from a
high level of statistical significance, implying that the
widespread deployment of cannabis and cannabinoids
for primarily commercial motivations is likely to carry
with it major negative mental health implications for the
future. Inverse probability weighting was employed to
transform data from a purely ecological observational
data series to a formal pseudo-randomized design.
Highly significant estimates and confidence intervals at
inverse probability-weighted robust and mixed effects regression together with large e-Values clearly indicate
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that these results fulfil the criteria for causal relationships. These epidemiological relationships are consistent
with numerous cellular and molecular mechanisms describing cannabis-related neurotoxicity.
We find these results to be of great concern not only
for the public health community within the USA but
also for the wider international community.
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